AU7101600A - Nitric oxide-producing hydrogel materials - Google Patents

Description

WO 01/15738 PCT/US00/24058 NITRIC OXIDE-PRODUCING HYDROGEL MATERIALS Field of the Invention The present invention relates to photopolymerizable hydrogel 5 materials that produce physiologically relevant amounts of nitric oxide (NO) for prolonged periods of time. This application claims priority to U.S.S.N. 60/152,054 filed September 2, 1999. Background of the Invention 10 Endothelial cells, normally present as a monolayer in the intimal layer of the arterial wall, are believed to play an important role in the regulation of smooth muscle cell proliferation in vivo. Endothelial cells are seriously disrupted by most forms of vascular injury, including that caused by percutaneous transluminal coronary angioplasty and similar procedures. 15 Approximately 35-50% of patients treated by percutaneous transluminal coronary angioplasty experience clinically significant renarrowing of the artery, or restenosis, within six months of the initial treatment. Restenosis is due, at least in part, to migration and proliferation of smooth muscle cells in the arterial wall along with increases in secretion of matrix proteins to form 20 an obstructive neointimal layer within the arterial wall. Similar issues limit the performance of vascular grafts. The processes that regulate arterial wound healing following vascular injury, such as that caused by angioplasty, are as yet poorly understood, but are believed to involve a complex cascade of blood and vessel wall-derived factors. 25 Numerous factors that stimulate intimal thickening and restenosis have been identified through administration of exogenous proteins, genetic alteration of cells, or through the blockade of certain signals using antibodies or other specific growth factor inhibitors. These smooth muscle cell mitogens and chemoattractants derive from both the blood or thrombus 30 formation and from the vessel wall itself. Endothelial cells produce a number of substances known to down-regulate smooth muscle cell proliferation, including heparin sulfate, prostacyclin (PG 12), and NO. 1 WO 01/15738 PCT/US00/24058 NO is an endothelium-derived target molecule useful for the prevention of restenosis because, in addition to limiting the proliferation of smooth muscle cells (Garg et al., 1989), NO reduces platelet aggregation (de Graaf et al., 1992; Radomski et al., 1987), increases endothelial cell 5 proliferation (Ziche et al., 1993), and attenuates leukocyte adhesion (Lefer et al., 1993), all of which are highly desirable for the reduction of intimal thickening and restenosis (Reviewed by Loscalzo, 1996). Because of the complexity of the restenotic process, approaches that act upon multiple targets are the most likely to be successful. 10 The mechanisms whereby NO affects these multiple responses are not fully understood as yet, but it is known that NO activates soluble guanylate cyclase by binding to its heme moiety, thereby elevating the levels of cyclic guanosine monophosphate (cGMP), an intracellular second messenger with multiple cellular effects (Moro et al., 1996). The effects of 15 NO can often be mimicked by the administration of cGMP or more stable derivatives of cGMP (Garg et al., 1989). In addition, NO has been found to inhibit ribonucleotide reductase, an enzyme that converts ribonucleotides into deoxy ribonucleotides, thus significantly impacting DNA synthesis (Lepoivre et al., 1991; Kwon et al., 1991), as well as several enzymes 20 involved in cellular respiration (Stuehr et al., 1989). A number of molecules that produce NO under physiological conditions (NO donors) have been identified and evaluated both in vitro and in vivo. NO donor molecules exert biological effects mimicking those of NO and include S-nitrosothiols (Diodati et al, 1993; Lefer et al., 1993; DeMeyer 25 et al., 1995), organic nitrates (Ignarro et al., 1981), and complexes of NO with nucleophiles (Diodati et al., 1993; Diodati et al., 1993; Maragos et al., 1993). Most of these have been low molecular weight molecules that are administered systemically and have short half-lives under physiologic conditions, thus exerting effects upon numerous tissue types with a brief 30 period of activity. In addition, L-arginine is often thought of as a NO donor, as L-arginine is a substrate for NO synthase, and thus administration of L arginine increases endogenous NO production and elicits responses similar to those caused by NO donors in most cases (Cooke et al., 1992). 2 WO 01/15738 PCT/US00/24058 The development of NO-releasing polymers containing NO/nucleophile complexes has been reported by Smith et al., (1996). These materials were capable of releasing NO for as long as 5 weeks in vitro and were able to limit smooth muscle cell proliferation in culture and to reduce 5 platelet adherence to vascular graft materials in an arterio-venous shunt model. These materials show promise for numerous clinical applications where localized NO production would be desired, such as anti-thrombotic coating materials for catheters, but probably will not be useful for the direct treatment of tissues in vivo as these materials suffer from a number of 10 disadvantages. These polymers may be produced as films, powders, or microspheres, but they cannot be formed in situ in direct contact with cells and tissues, thus making it difficult to strictly localize NO treatment to a tissue and potentially causing issues with the retention of the polymer at the site of application. The formulation issues will also make local 15 administration during laparoscopic or catheter-based procedures difficult or impossible. Additionally, biocompatibility of the base polymer is a serious issue for implantable, NO-releasing polymers, especially those intended for long-term use, as inflammatory and thrombotic responses may develop after the cessation of NO release. 20 It would be more efficient if these compounds could be administered solely to the site in need of treatment, and in some cases, reduce or eliminate side effects due to systemic administration of the agents, particularly over prolonged time periods. It is therefore an object of the present invention to provide reagents 25 for controlled release of NO and/or compounds modulating NO levels at a particular site, following local or topical application. It is a further object of the present invention to provide methods for treatment of conditions involving inflammatory responses by providing hydrogel materials releasing compound modulating NO levels at the site of 30 application. Summary of the Invention Biocompatible polymeric materials releasing or producing NO, most preferably photopolymerizable biodegradable hydrogels capable of releasing 3 WO 01/15738 PCT/US00/24058 physiological amounts of NO for prolonged periods of time, are applied to sites on or in a patient in need of treatment thereof for disorders such as restenosis, thrombosis, asthma, wound healing, arthritis, penile erectile dysfunction or other conditions where NO plays a significant role. The 5 polymeric materials can also be formed into films, coatings, or microparticles. The polymers are typically formed of macromers, which preferably include biodegradable regions, and have bound thereto groups that are released in situ to elevate or otherwise modulate NO levels at the site where treatment is needed. The macromers can form a homo or hetero 10 dispersion or solution, which is polymerized to form a polymeric material, that in the latter case can be a semi-interpenetrating network or interpenetrating network. Compounds to be released can be physically entrapped, covalently or ionically bound to macromer, or actually form a part of the polymeric material. Hydrogels can be formed by ionic and/or covalent 15 crosslinking. Other active agents, including therapeutic, prophylactic, or diagnostic agents, can also be included within the polymeric material. Brief Description of the Invention Figure 1 is a schematic of the synthesis of S-nitrosocysteine hydrogels (Acryloyl-PEG-CYSNO). 20 Figure 2 is a schematic of the synthesis of acryloyl-PEG-Lysine 5

NO

nucleophile complex hydrogels. Figure 3 is a schematic of the synthesis of acryloyl-PEG-DETA-NO nucleophile complex hydrogels. Figure 4 is a graph showing the temporal release (%NO released over 25 time in days) of NO from acryloyl-PEG-Lyss-NO hydrogels at pH 7.4 (circles) and pH 3 (squares). Figure 5 is a graph showing the temporal release (%NO released over time in days) of NO from acryloyl-PEG-DETA-NO hydrogels at pH 7.4 (circles) and pH 2 (squares). 30 Figure 6 is a graph showing the temporal release (%NO released over time in hours) of NO from PEG-CYSNO hydrogels at pH 7.4 (circles) and pH 2 (squares). 4 WO 01/15738 PCT/US00/24058 Figure 7 is a graph showing the temporal release (pimol NO released per gram of polymer over time in hours) of NO from PVA-NO-bFGF hydrogels at pH 7.4, 37 0 C. Figures 8A and 8B are graphs showing that acryloyl-PEG-Lysine-NO 5 hydrogels inhibit the proliferation of smooth muscle cells. Figure 8A, % of control cell number, hydrogel formulation. Figure 8B, % of control cell number, soluble polymer. Figures 9A and 9B are graphs showing the inhibition of SMC proliferation by NO released from acryloyl-PEG-DETA-NO hydrogels 10 (Figure 9A) and soluble polymer (Figure 9B), as a percentage of the control. Figures 10 A and 10B are graphs showing inhibition of SMC proliferation by NO released from acryloyl-PEG-CYSNO hydrogels (Figure 10A) and soluble polymer (Figure 10B), as a percentage of controls. Figure 11 is a graph comparing the degree of inhibition of smooth 15 muscle cell growth by NO released from hydrogels: acryloyl-PEG-Lys-NO, acryloyl-PEG-DETA-NO, and acryloyl-PEG-CYSNO, compared to control hydrogel with NO. The %inhibition of smooth muscle cell growth is determined by comparing the cell growth for each NO-releasing hydrogel to a control PEG-diacrylate hydrogel. 20 Figure 12a is a graph showing the temporal release of NO, micromolar NO released/gram of gel over time in hoursfrom PVA-NO-bFGF hydrogels at pH 7.4, 37 0 C. Figure 12b is a graph showing the temporal release (% of theoretical bFGF released per gram of gel over time in hours) from PVA-Cys-NO-bFGF hydrogels at pH 7.4, 37 0 C. 25 Detailed Description of the Invention I. Polymeric Materials for Release of NO The polymeric materials are biocompatible and release or produce NO. In various preferred embodiments, the polymers are also biodegradable, form hydrogels, polymerize in situ and are tissue adherant. These properties 30 are conferred by the selection of the macromer components as well as addition of various groups to the components. 5 WO 01/15738 PCT/US00/24058 The term "polymerizable" means that the regions have the capacity to form additional covalent bonds resulting in macromer interlinking, for example, carbon-carbon double bonds of acrylate-type molecules. Such polymerization is characteristically initiated by free-radical formation 5 resulting from photon absorption of certain dyes and chemical compounds to ultimately produce free-radicals, although it can be obtained using other methods and reagents known to those skilled in the art. A. Polymeric Materials The polymeric materials must be biocompatible, i.e., not eliciting a 10 significant or unacceptable toxic or immunogenic response following administration to or implantation into an individual. A number of polymeric materials are known which are biocompatible, including both natural and synthetic polymers. Examples include proteins (of the same origin as the recipient), polysaccharides such as 15 chondroitin sulfate and hyaluronic acid, polyurethanes, polyesters, polyamides, and acrylates. Polymers can be degradable or non-degradable. Most polymeric materials will be selected based on a combination of properties conferred by the various components, which may include a water soluble regions such as PEG or PVA, biodegradable regions such as regions 20 that degrade hydrolytically, and groups that can be used to polymerize the macromers in situ. Water-Soluble and/or Tissue Adhesive Regions There are a variety of water soluble materials that can be incorporated into the polymers. The term "at least substantially water 25 soluble" is indicative that the solubility should be at least about 5 g/100 ml of aqueous solution. In preferred embodiments, the core water soluble region can consist of poly(ethylene glycol), poly(ethylene oxide), poly(vinyl acetate), poly(vinyl alcohol), poly(vinylpyrrolidone), poly(ethyloxazoline), poly(ethylene oxide)-co-poly(propyleneoxide) block copolymers, 30 polysaccharides or carbohydrates such as hyaluronic acid, dextran, heparan sulfate, chondroitin sulfate, heparin, or alginate, or proteins such as gelatin, collagen, albumin, or ovalbumin. Hydrophilic (i.e., water soluble) regions will generally be tissue 6 WO 01/15738 PCT/US00/24058 adhesive. Both hydrophobic and hydrophilic polymer including large number of exposed carboxylic groups will be tissue or bioadhesive. Ligands such as RGD peptides and lectins which bind to carbohydrate molecules on cells can also be bound to the polymer to increase tissue adhesiveness. 5 Degradable Regions Polyesters (Holland et al., 1986 Controlled Release, 4:155-180) of a hydroxy acids (viz., lactic acid, glycolic acid), are the most widely used biodegradable materials for applications ranging from closure devices (sutures and staples) to drug delivery systems (U.S. Patent No. 4,741,337 to 10 Smith et al.; Spilizewski et al., 1985 . Control. Rel. 2:197-203). In addition to the poly(hydroxy acids), several other polymers are known to biodegrade, including polyanhydrides and polyorthoesters, which take advantage of labile backbone linkages, as reported by Domb et al., 1989 Macromolecules, 22:3200; Heller et al., 1990 Biodegradable Polymers as Drug Delivery 15 Systems, Chasin, M. and Langer, R., Eds., Dekker, New York, 121-161. Polyaminoacids have also been synthesized since it is desirable to have polymers that degrade into naturally occurring materials, as reported by Miyake et al., 1974, for in vivo use. The time required for a polymer to degrade can be tailored by 20 selecting appropriate monomers. Differences in crystallinity also alter degradation rates. Due to the relatively hydrophobic nature of these polymers, actual mass loss only begins when the oligomeric fragments are small enough to be water soluble. Hence, initial polymer molecular weight influences the degradation rate. 25 The biodegradable region is preferably hydrolyzable under in vivo conditions. Hydrolyzable groups may be polymers and oligomers of glycolide, lactide, e-caprolactone, other ac-hydroxy acids, and other biologically degradable polymers that yield materials that are non-toxic or present as normal metabolites in the body. Preferred poly(ac-hydroxy acid)s 30 are poly(glycolic acid), poly(DL-lactic acid) and poly(L-lactic acid). Other useful materials include poly(amino acids), poly(anhydrides), poly(orthoesters), and poly(phosphoesters). Polylactones such as poly(s 7 WO 01/15738 PCT/US00/24058 caprolactone), poly(e-caprolactone), poly(8-valerolactone) and poly(gamma butyrolactone), for example, are also useful. Biodegradable regions can also be constructed from polymers or monomers using linkages susceptible to biodegradation by enzymes, such as 5 ester, peptide, anhydride, orthoester, and phosphoester bonds. Degradable materials of biological origin are well known, for example, crosslinked gelatin. Hyaluronic acid has been crosslinked and used as a degradable swelling polymer for biomedical applications (U.S. Patent No. 4,987,744 to della Valle et al., U.S. Patent 4,957,744 to Della Valle et al. (1991) Polym. 10 Mater. Sci. Eng., 62:731-735]). Biodegradable Hydrogels A number of polymers have been described which include both water soluble regions and biodegradable regions. Sawhney et al., (1990) J. Biomed Mater. Res. 24:1397-1411, copolymerized lactide, glycolide and 6 15 caprolactone with PEG to increase its hydrophilicity and degradation rate. U.S. Patent No. 4,716,203 to Casey et al. (1987) synthesized a PGA-PEG PGA block copolymer, with PEG content ranging from 5-25% by mass. U.S. Patent No. 4,716,203 to Casey et al. (1987) also reports synthesis of PGA-PEG diblock copolymers, again with PEG ranging from 5-25%. U.S. 20 Patent No. 4,526,938 to Churchill et al. (1985) described noncrosslinked materials with MW in excess of 5,000, based on similar compositions with PEG; although these materials are not water soluble. Cohn et al. (1988) J Biomed. Mater. Res. 22:993-1009 described PLA-PEG copolymers that swell in water up to 60%; these polymers also are not soluble in water, and 25 are not crosslinked. The features that are common to these materials is that they use both water-soluble polymers and degradable polymers, and that they are insoluble in water, collectively swelling up to about 60%. U.S. Patent No. 5,410,016 issued on April 25, 1995 to Hubbell, et al., describes materials which are based on polyethylene glycol (PEG), because of 30 its high biocompatible and thromboresistant nature, with short polylactide extensions to impart biodegradation and acrylate termini to allow rapid photopolymerization without observable heat production. These materials are 8 WO 01/15738 PCT/US00/24058 readily modified to produce hydrogels which release or produce NO. The polymerizable regions are separated by at least one degradable region to facilitate uniform degradation in vivo. There are several variations of these polymers. For example, the polymerizable regions can be attached 5 directly to degradable extensions or indirectly via water soluble nondegradable sections so long as the polymerizable regions are separated by a degradable section. For example, if the macromer composition contains a simple water soluble region coupled to a degradable region, one polymerizable region may be attached to the water soluble region and the 10 other attached to the degradable extension or region. In another embodiment, the water soluble region forms the central core of the macromer composition and has at least two degradable regions attached to the core. At least two polymerizable regions are attached to the degradable regions so that, upon degradation, the polymerizable regions, particularly in the 15 polymerized gel form, are separated. Conversely, if the central core of the macromer composition is formed by a degradable region, at least two water soluble regions can be attached to the core and polymerizable regions attached to each water soluble region. The net result will be the same after gel formation and exposure to in vivo degradation conditions. 20 In another embodiment, the macromer composition has a water soluble backbone region and a degradable region affixed to the macromer backbone. At least two polymerizable regions are attached to the degradable regions, so that they are separated upon degradation, resulting in gel product dissolution. In a further embodiment, the macromer backbone is formed of a 25 nondegradable backbone having water soluble regions as branches or grafts attached to the degradable backbone. Two or more polymerizable regions are attached to the water soluble branches or grafts. In another variation, the backbone may be star shaped, which may include a water soluble region, a biodegradable region or a water soluble region which is also biodegradable. 30 In this general embodiment, the star region contains either water soluble or biodegradable branches or grafts with polymerizable regions attached thereto. Again, the polymerizable regions must be separated at some point by a degradable region. 9 WO 01/15738 PCT/US00/24058 Polymerizable groups. The polymerizable regions are preferably polymerizable by photoinitiation by free radical generation, most preferably in the visible or long wavelength ultraviolet radiation. The preferred polymerizable regions 5 are acrylates, diacrylates, oligoacrylates, dimethacrylates, oligomethoacrylates, or other biologically acceptable photopolymerizable groups. A preferred tertiary amine is triethanol amine. Useful photoinitiators are those which can be used to initiate by free radical generation polymerization of the macromers without cytotoxicity and 10 within a short time frame, minutes at most and most preferably seconds. Preferred dyes as initiators of choice for LWUV initiation are ethyl eosin, 2,2-dimethoxy-2-phenyl acetophenone, other acetophenone derivatives, and camphorquinone. In all cases, crosslinking and polymerization are initiated among copolymers by a light-activated free-radical polymerization initiator 15 such as 2,2-dimethoxy-2-phenylacetophenone or a combination of ethyl eosin (10 -10 - 2 milliM) and triethanolamine (0.001 to 0.1 M), for example. The choice of the photoinitiator is largely dependent on the photopolymerizable regions. For example, when the macromer includes at least one carbon-carbon double bond, light absorption by the dye causes the 20 dye to assume a triplet state, the triplet state subsequently reacting with the amine to form a free radical which initiates polymerization. Preferred dyes for use with these materials include eosin dye and initiators such as 2,2 dimethyl-2-phenylacetophenone, 2-methoxy-2-phenylacetophenone, and camphorquinone. Using such initiators, copolymers may be polymerized in 25 situ by long wavelength ultraviolet light or by laser light of about 514 nm, for example. Initiation of polymerization is accomplished by irradiation with light at a wavelength of between about 200-700 nm, most preferably in the long wavelength ultraviolet range or visible range, 320 nm or higher, most 30 preferably about 514 nm or 365 nm. There are several photooxidizable and photoreducible dyes that may be used to initiate polymerization. These include acridine dyes, for example, acriblarine; thiazine dyes, for example, thionine; xanthine dyes, for example, 10 WO 01/15738 PCT/US00/24058 rose bengal; and phenazine dyes, for example, methylene blue. These are used with cocatalysts such as amines, for example, triethanolamine; sulphur compounds, for example, RSO 2 R'; heterocycles, for example, imidazole; enolates; organometallics; and other compounds, such as N-phenyl glycine. 5 Other initiators include camphorquinones and acetophenone derivatives. Thermal polymerization initiator systems may also be used. Such systems that are unstable at 37'C and would initiate free radical polymerization at physiological temperatures include, for example, potassium persulfate, with or without tetramethyl ethylenediamine; 10 benzoylperoxide, with or without triethanolamine; and ammonium persulfate with sodium bisulfite. Other initiation chemistries may be used besides photoinitiation. These include, for example, water and amine initiation schemes with isocyanate or isothiocyanate containing macromers used as the 15 polymerizable regions. Preferred Embodiments In the preferred embodiment, the polymeric materials are a biodegradable, polymerizable and at least substantially water soluble macromer composition. The first macromer includes at least one water 20 soluble region, at least one NO carrying region and at least one free radical polymerizable region. The second macromer includes at least one water soluble region and at least two free radical polymerizable regions. The regions can, in some embodiments, be both water soluble and biodegradable. The macromer composition is polymerized by exposure of the polymerizable 25 regions to free radicals generated, for example, by photosensitive chemicals and dyes. Examples of these macromers are PVA or PEG-oligoglycolyl acrylates. The choice of appropriate end caps permits rapid polymerization and gelation. Acrylates are preferred because they can be polymerized using 30 several initiating systems, e.g., an eosin dye, by brief exposure to ultraviolet or visible light. A poly(ethyleneglycol) or PEG central structural unit (core) is preferred on the basis of its high hydrophilicity and water solubility, 11 WO 01/15738 PCT/US00/24058 accompanied by excellent biocompatibility. A short oligo or poly(ot hydroxy acid), such as polyglycolic acid, is selected as a preferred chain extension because it rapidly degrades by hydrolysis of the ester linkage into glycolic acid, a harmless metabolite. Although highly crystalline 5 polyglycolic acid is insoluble in water and most common organic solvents, the entire macromer composition is water-soluble and can be rapidly gelled into a biodegradable network while in contact with aqueous tissue fluids. Such networks can be used to entrap and homogeneously disperse water soluble drugs and enzymes and to deliver them at a controlled rate. Further, 10 they may be used to entrap particulate suspensions of water-insoluble drugs. Other preferred chain extensions are polylactic acid, polycaprolactone, polyorthoesters, and polyanhydrides. Polypeptides may also be used. Such "polymeric" blocks should be understood to include timeric, trimeric, and oligomeric blocks. 15 PVA contains many pendant hydroxyl groups. These hydroxyl groups are easily reacted to form side chains such as various crosslinking agents and nitric oxide donors. PVA is water soluble and has excellent biocompatiblity. Modification of PVA to attach methacrylate groups via a diacetal bond with the pendant hydroxyl groups and addition of an 20 appropriate photoinitiator enables the PVA to be photopolymerized to form hydrogels under long wavelength UV light. In another preferred embodiment, the hydrogel is formed from modified polyvinyl alcohol (PVA) macromers, such as those described in U.S. Patent Nos. 5,508,317,5,665,840, 5,849,841, 5,932,674, 6,011,077, 5,939,489, and 5,807,927. The macromers 25 disclosed in U.S. Patent No. 5,508,317, for example, are PVA prepolymers modified with pendant crosslinkable groups, such as acrylamide groups containing crosslinkable olefinically unsaturated groups. These macromers can be polymerized by photopolymerization or redox free radical polymerization, for example. The starting polymers are, in particular, 30 derivatives of polyvinyl alcohol or copolymers of vinyl alcohol that contain, for example, a 1,3-diol skeleton. The crosslinkable group or the further modifier can be bonded to the starting polymer skeleton in various ways, for 12 WO 01/15738 PCT/US00/24058 example through a certain percentage of the 1,3-diol units being modified to give a 1,3-dioxane, which contains a crosslinkable radical, or a further modifier in the 2-position. Another possibility is for a certain percentage of hydroxyl groups in the starting polymer to be esterified by means of an 5 unsaturated organic acid, these ester-bonded radicals containing a crosslinkable group. The hydrophobicity of these macromers can be increased by substituting some of the pendant hydroxyl groups with more hydrophobic substituents. The properties of the macromers, such as hydrophobicity, can also be modified by incorporating a comonomer in the 10 macromer backbone. The macromers can also be formed having pendant groups crosslinkable by other means. B. NO groups or Modulating Compounds A number of molecules that produce NO under physiological conditions (NO donors) have been identified and evaluated both in vitro and 15 in vivo, including S-nitrosothiols, organic nitrates, and complexes of NO with nucleophiles. L-arginine is a NO donor, since L-arginine is a substrate for NO synthase, and thus administration of L-arginine increases endogenous NO production and elicits responses similar to those caused by NO donors in most cases. Other NO donors include molsidomine, CAS754, SPM-5185, 20 and SIN-1. Other compounds capable of producing and/or donating NO may also be used. These include organic nitrates, nitrosylating, compounds, nitrosoesters, and L-arginine. The molecules which produce NO, or release or generate NO, are preferably attached to regions containing nucleophiles and/or thiols such as 25 S-nitrosothiols capable of forming a complex with NO. C. Prophylactic, Therapeutic and Diagnostic Agents The polymeric materials can also be used for drug delivery, preferably localized release of prophylactic, therapeutic or diagnostic agents at the site where the materials are needed, although the polymeric materials 30 can be loaded with agent to be released systemically. These agents include proteins or peptides, polysaccharides, nucleic acid molecules, and simple organic molecules, both natural and synthetic. Representative materials include antibiotics, antivirals, and antifungal drugs, anti-inflammatories 13 WO 01/15738 PCT/US00/24058 (steroidal or non-steroidal), hormones, growth factors, cytokines, neuroactive agents, vasoconstrictors and other molecules involved in the cardiovascular responses, enzymes, antineoplastic agents, local anesthetics, antiangiogenic agents, antibodies, drugs affecting reproductive organs, and oligonucleotides 5 such as antisense oligonucleotides. Diagnostic materials may be radioactive, bound to or cleave a chromogenic substrate, or detectable by ultrasound, x ray, mri, or other standard imaging means. These agents can be mixed with macromer prior to polymerization, applied into or onto the polymer, or bound to the macromer prior to or at the 10 time of polymerization, either covalently or ionically, so that the agent is released by degradation (enzymatic or hydrolytic) or diffusion at the site where the polymer is applied. II. Methods of Use A. Coatings; Films; Microparticles 15 Although described primarily with respect to in vivo treatment, it is apparent that the polymeric materials described herein can be used in cell culture, on cell culture substrates, or as coatings on medical implants or devices such as stents or catheters, or formed using standard techniques into microparticles or other types of formulations which may be used in or 20 administered to a patient. B. Therapeutic Applications Polymeric materials capable of releasing physiological amounts of NO for prolonged periods of time can be applied to sites on or in a patient in need of treatment thereof. Representative disorders or conditions that can be 25 treated with NO include restenosis, thrombosis, asthma, wound healing, arthritis, and penile or female erectile dysfunction. The material is typically applied as a macromer solution and polymerized in situ, although polymerization can be initiated prior to application. Wound Healing 30 The formulations are particularly useful for treatment of wounds, such as ulcers and burns. ... all types of wounds, including burns, surgical wounds, and open leg and foot wounds. There are generally three types of open leg wounds, termed ulcers: venous stasis ulcers, generally seen in 14 WO 01/15738 PCTIUS00/24058 sedentary elderly people when blood flow to the leg becomes sluggish; decubitus ulcers, also termed pressure sores or bed sores, which occurs most often in people who are bedridden and are unable to frequently change position; and diabetic foot ulcers, caused by poor blood circulation to the 5 feet. Due to the aging of the population, there will likely be a greater demand for effective and user friendly wound treatments in the near future. The term "wound" as used herein refers to all types of tissue injuries, including those inflicted by surgery and trauma, including burns, as well as injuries from chronic or acute medical conditions, such as atherosclerosis or 10 diabetes. Treatment of Restenosis A preferred application is a method of reducing the effects of restenosis on post-surgical patients. The method includes coating the surface within an artery with an aqueous solution of light-sensitive free radical 15 polymerizable initiator and a number of macromers. The coated artery is subjected to a Xenon arc laser inducing polymerization of the macromers. As the newly polymerized macromer composition is formed, the physiological conditions within the artery will induce the release of NO. This release will be strictly localized for prolonged periods of time. 20 Prevention ofSurgical Adhesions. A preferred application is a method of reducing formation of adhesions after a surgical procedure in a patient. In one embodiment the method includes coating damaged tissue surfaces in a patient with an aqueous solution of a light-sensitive free-radical polymerization initiator and 25 a macromer solution as described above. The coated tissue surfaces are exposed to light sufficient to polymerize the macromer. The light-sensitive free-radical polymerization initiator may be a single compound (e.g., 2,2 dimethoxy-2-phenyl acetophenone) or a combination of a dye and a cocatalyst (e.g., ethyl eosin and triethanol amine). 30 Tissue Adhesives. Another use of the polymers is in a method for adhering tissue surfaces in a patient. In one embodiment the macromer is mixed with a photoinitiator or photoinitiator/cocatalyst mixture to form an aqueous 15 WO 01/15738 PCT/US00/24058 mixture and the mixture is applied to a tissue surface to which tissue adhesion is desired. The tissue surface is contacted with the tissue with which adhesion is desired, forming a tissue junction. The tissue junction is then irradiated until the macromers are polymerized. 5 Tissue Coatings. In a particularly preferred application of these macromers, an ultrathin coating is applied to the surface of a tissue, most preferably the lumen of a tissue such as a blood vessel. One use of such a coating is in the treatment or prevention of restenosis, abrupt reclosure, or vasospasm after 10 vascular intervention. An initiator is applied to the surface of the tissue, allowed to react, adsorb or bond to tissue, the unbound initiator is removed by dilution or rinsing, and the macromer solution is applied and polymerized. This method is capable of creating uniform polymeric coating of between one and 500 microns in thickness, most preferably about twenty microns, 15 which does not evoke thrombosis or localized inflammation. Tissue Supports. The polymeric materials can also be used to create tissue supports by forming shaped articles within the body to serve a mechanical function. Such supports include, for example, sealants for bleeding organs, sealants for 20 bone defects and space-fillers for vascular aneurisms. Further, such supports can include strictures to hold organs, vessels or tubes in a particular position for a controlled period of time. Controlled drug delivery. As noted above, the polymeric materials can be use as carriers for 25 biologically active materials such as therapeutic, prophylactic or diagnostic agents, including hormones, enzymes, antibiotics, antineoplastic agents, and cell suspensions. The polymeric material may be used to temporarily preserve functional properties of an agent to be released, as well as provide prolonged, controlled release of the agent into local tissues or systemic 30 circulation. In a variation of the method for controlled drug delivery in which agent is mixed with the macromer solution then polymerized in situ, the macromers are polymerized with the biologically active materials to form 16 WO 01/15738 PCT/US00/24058 microspheres or nanoparticles containing the biologically active material. The macromer, photoinitiator, and agent to be encapsulated are mixed in an aqueous mixture. Particles of the mixture are formed using standard techniques, for example, by mixing in oil to form an emulsion, forming 5 droplets in oil using a nozzle, or forming droplets in air using a nozzle. The suspension or droplets are irradiated with a light suitable for photopolymerization of the macromer. These materials are particularly useful for controlled drug delivery of hydrophilic materials, since the water soluble regions of the polymer enable 10 access of water to the materials entrapped within the polymer. Moreover, it is possible to polymerize the macromer composition containing the material to be entrapped without exposing the material to organic solvents. Release may occur by diffusion of the material from the polymer prior to degradation and/or by diffusion of the material from the polymer as it degrades, 15 depending upon the characteristic pore sizes within the polymer, which is controlled by the molecular weight between crosslinks and the crosslink density. Deactivation of the entrapped material is reduced due to the immobilizing and protective effect of the gel and catastrophic burst effects associated with other controlled-release systems are avoided. When the 20 entrapped material is an enzyme, the enzyme can be exposed to substrate while the enzyme is entrapped, provided the gel proportions are chosen to allow the substrate to permeate the gel. Degradation of the polymer facilitates eventual controlled release of free macromolecules in vivo by gradual hydrolysis of the terminal ester linkages. 25 III. Examples As demonstrated by examples 1-3, three classes of NO-producing, PEG-based polymers have been synthesized and their NO release rate constants determined in vitro under physiological conditions. The biological response to appropriate materials has been evaluated in vitro using cultured 30 smooth muscle cells and endothelial cells and in vivo using a rat carotid artery injury model that resembles restenosis in man. The materials include BAB block copolymers of polyethylene glycol (A) with polycysteine (B) that are subsequently reacted with NaNO 2 to form S-nitrosothiols, BAB block 17 WO 01/15738 PCT/US00/24058 copolymers of polyethylene glycol ("PEG") (A) and diethylenetriamine ("DETA") (B) that are subsequently reacted with NO gas to form nucleophile/NO complexes, and BAB block copolymers of polyethylene glycol (A) and polylysine (B) that are subsequently reacted with NO gas to 5 form nucleophile/NO complexes. All polymers are further terminated with reactive acrylate groups to allow rapid photopolymerization in situ. Such materials would be expected to have good biocompatibility, provided that a water soluble, biocompatible polymer such as PEG comprises the bulk of the material and has a sufficiently high molecular 10 weight, and to slowly biodegrade due to the presence of two ester bonds and two amide bonds in each polymer chain. These three materials were selected as they are expected to have vastly different release kinetics: nucleophile/NO complexes have been shown to release NO for up to 5 weeks (Smith el al., 1996), while the half-life of S-nitrosocysteine is 0.023 hours (Mathews et al., 15 1993). The amount of NO produced by these copolymers may be tailored by altering the ratio of polyethylene glycol (PEG) to cysteine or lysine. An advantage of these macromer compositions are that they can be polymerized rapidly in an aqueous surrounding. Precisely conforming, semi permeable, biodegradable films or membranes can thus be formed on tissue 2 0 in situ to serve as biodegradable barriers, as carriers for living cells or other biologically active materials, and as surgical adhesives. The polymer shows excellent biocompatibility, as seen by a minimal fibrous overgrowth on implanted samples. Hydrogels for the models were gelled in situ from water-soluble precursors by brief exposure to long wavelength ultraviolet 25 (LWUV) light, resulting in formation of an interpenetrating network of the hydrogel with the protein and glycosaminoglycan components of the tissue. As demonstrated by examples 4 and 5, three types of PVA hydrogels were made and demonstrated release of NO and incorporated drug (bFGF):

PVA-NH

2 -NO hydrogels; PVA-Cys-NO hydrogels; PVA-NO-bFGF 30 hydrogels. The results are similar to those for the PEG based hydrogels. Example 1: Synthesis of PEG-Cys Macromers As shown in Figure 1, an acryloyl-PEG-CYSNO polymer was formed by first reacting polyethylene glycol N-hydroxysuccinimide 18 WO 01/15738 PCT/US00/24058 monoacrylate (ACRL-PEG-NHS, MW 3400, commercially available from Shearwater Polymers, Huntington, AL) with L-cysteine at an 1:2 molar ratio in 50 mM sodium bicarbonate buffer (pH 8.5) for 2 hours; the product was then dialyzed in a cellulose ester membrane (Molecular weight cutoff 500, 5 Spectrum Labs, Laguna Hills, CA) in diH 2 0, and lyophilized. Analysis of the acryloyl-PEG-Cys copolymer was performed using gel permeation chromatography (GPC) with an evaporative light scattering detector and a UV detector at 260 nm (Polymer Laboratories, Amherst, MA). Successful synthesis of acryloyl-PEG-Cys was determined by a shift in the position of 10 the peak from the evaporative light scattering detector. The copolymer was then reacted with an equimolar amount of NaNO 2 at pH 2 and 37 0 C for 20 minutes to form S-nitrosocysteine. Conversion of thiol groups to S nitrosothiols was measured using the Ellman's assay (Hermanson, 1995). After adjusting the pH of the solution to 7.4, the acryloyl-PEG-CYSNO 15 polymer was incorporated into photopolymerizable hydrogels by mixing with PEG-diacrylate (MW 3400) at a 1:10 molar ratio in aqueous solution with 1500 ppm 2,2-dimethoxy-2-phenyl acetophenone as a long wavelength ultraviolet initiator. 0.15% N-vinylpyrrolidone was present in this mixture as it was used as a solvent for the photoinitiator. Exposure to UV light (365 20 nm, 10 mW/cm 2 ) was used to crosslink the polymer, resulting in conversion to a hydrogel (Sawhney et al., 1993). Production of NO by the hydrogels was quantified using the Griess assay. Example 2: Synthesis of PEG-Lys Macromers. As shown in Figure 2, for acryloyl-PEG-Lyss-NO hydrogels, a 25 copolymer of ACRL-PEG-NHS (MW 3400, Shearwater Polymers) and poly-L-lysine (DP=5) was synthesized by reacting at an equimolar ratio in 50 mM sodium bicarbonate (pH 8.5). The resultant copolymer was analyzed via GPC, then dissolved in water and reacted with NO gas in an evacuated vessel, thus forming NO-nucleophile complexes with the amine 30 groups on the lysine side groups. The extent of conversion of amine groups to NO-nucleophile complexes was measured using the ninhydrin assay, and crosslinked hydrogels were formed as described above in Example 1. 19 WO 01/15738 PCT/US00/24058 Example 3: Synthesis of DETA-NO-nucleophile complex hydrogels. Diethylenetriamine (DETA, Aldrich, Milwaukee, WI) was reacted with ACRL-PEG-NHS (MW 3400, Shearwater Polymers) in 50 mM sodium bicarbonate buffer (pH 8.5) at an equimolar ratio, lyophilized, and analyzed 5 via GPC as described above. The copolymer was then dissolved in water and exposed to NO gas to form NO-nucleophile complexes as described for PEG-Lyss-NO and assayed for amine content using the ninhydrin assay. The PEG-DETA-NO was lyophilized and then photopolymerized as described above to form hydrogels, as shown in Figure 3. 10 Example 4: Synthesis of PVA-NH 2 -NO hydrogels Poly(vinyl alcohol) (Hoechst, Mowiol 4-88) was dissolved in diH20 and warmed to 95oC in a round bottom flask under continuous stirring. After one hour, the solution was cooled to room temperature, and a crosslinkable acetal group, methacrylamidoacetaldehyde dimethyl acetal (NAAADA) was 15 added. The amine acetal, gamma-aminobutyraldehyde diethyl acetal, was also added, and the mixture was acidified using glacial acetic acid and 37% hydrochloric acid. The mixture was allowed to stir at room temperature for nine hours, after which the pH was adjusted to pH 3.6 using triethylamine. In order to purify the polymer, the solution was then diafiltered through a 20 MW 3000 cellulose membrane against diH 2 0 at 6.5 times the volume of polymer solution. The polymer concentration was adjusted to 22% w/v using diafiltration, and the pH was adjusted to 7.4 with 1N NaOH. The amine concentration of the polymer was determined using the ninhydrin assay. 25 In order to form the NO donor bound to the PVA-NH 2 , the neutralized amine-modified polymer was placed in a round bottom flask with stopcock. The flask was evacuated and filled with nitric oxide gas until the desired conversion of amines to NO nucleophile complexes was achieved. Photocrosslinked hydrogels were formed from the PVA-NH 2 -NO by adding 30 0.1% Irgacure 2959 (Ciba-Geigy) photoinitiator (based on total solution volume) and then exposing to UV light (2 mW/cm 2 , 365 nm) for 30 seconds. 20 WO 01/15738 PCT/US00/24058 Addition of the photoinitiator brings the final polymer concentration to 20% w/v. Example 5: Synthesis of PVA-Cys-NO hydrogels

PVA-NH

2 was synthesized as described above. The amine terminus 5 of cysteine was acetylated using acetic anhydride, and the carboxyl end of the cysteine was coupled to the PVA-NH 2 using water-soluble EDAC chemistry. The resulting PVA-Cys was then purified using diafiltration and brought to a concentration of 22% w/v. PVA-Cys-NO was formed by adding sodium nitrite at an equimolar amount to cysteine residues, adjusting 10 the pH to 2, and incubating at 37 0 C for 15 minutes. The extent of reaction of cysteine to Cys-NO was assayed using both the Ellman's and Griess reactions. The photoinitiator, 2,2-methyl-2-phenylacetophenone was dissolved in N-vinylpyrrolidone at a concentration of 600 mg/ml and added to the polymer solution (0.1% based on total solution volume). The polymer 15 was then crosslinked under UV light for 30 seconds and placed in HEPES buffered saline, pH 7.4, 37'C. Example 6: Release of bFGF from PVA-NO-bFGF hydrogels. For PVA-NO-bFGF hydrogels, the above procedure was used to make the PVA-NO polymer. Immediately prior to exposure to UV light, 25 20 pg/ml bFGF was added to the polymer solution and mixed well. Gels were crosslinked as described earlier and stored in HEPES buffered saline, pH 7.4, 37 0 C. Release ofbFGF was quantified using the BCA assay (Pierce Chemicals), and NO release was assayed using the Griess reaction. Example 7: NO-release Rates from acryloyl-PEG-Lyss-NO hydrogels 25 Following preparation and photopolymerization of the NO-releasing materials as described above, the hydrogels were weighed and stored in HEPES buffered saline, pH 7.4, at 37 0 C. Aliquots of the buffer were removed at each time point and replaced with fresh buffer. The samples from each time point were then analyzed for nitrite content using a 30 colorimetric assay based on the Griess reaction. NO release kinetics of hydrogels stored in buffer at various pH levels were also investigated in order to explore possible storage conditions for the 21 WO 01/15738 PCT/US00/24058 hydrogels. At acidic pH levels, release of NO from the hydrogels was significantly inhibited. NO release from acryloyl-PEG-Lyss-NO hydrogels is shown in Figure 4. 5 NO release from acryloyl -PEG-DETA-NO hydrogels is shown in Figure 5. NO release from acryloyl-PEG-CYSNO hydrogels is shown in Figure 6. Example 8: NO-release Rates from PVA-NO-bFGF hydrogels 10 The release of NO release from PVA-NO-bFGF hydrogels was determined in the same manner as Example 7 and is shown in Figure 7. Figures 12a and 12b, respectively, show the temporal release of NO and a growth factor, bFGF, over time from PVA-NO-bFGF hydrogels. Release of NO continues for well over 12 hours, while the growth factor is 15 completely released within the first 5 hours. Example 9: Effects of NO-releasing Macromers on Cultured Smooth Muscle Cells: Proliferation and Viability In order to assess the potential of a material for the reduction of smooth muscle cell proliferation after vascular injury, cultured smooth 20 muscle cells were grown in the presence of NO-releasing materials, and the effects of those materials on the cells evaluated. Smooth muscle cells isolated from Wistar-Kyoto rats (passage 11-15, provided by T. Scott Burden) were cultured in Minimum Essential Medium supplemented with 10% FBS, 2 mM L-glutamine, 500 units penicillin, and 100 mg/L 25 streptomycin, at 37 0 C in a 5% CO 2 environment. The cells were seeded into 24-well tissue culture plates (Becton Dickinson, Franklin Lakes, NJ) at a density of 10,000 cells/cm 2 . NO donors in either soluble or hydrogel form were added to the media in the wells one day after seeding. At 4 days culture, cell numbers were determined by preparing single cell suspensions 30 with trypsin and counting three samples from each group using a Coulter counter (Multisizer #0646, Coulter Electronics, Hialeah, FL). The effects of NO donors in solution on the proliferation of SMCs were first investigated by performing a NO dose response curve, whereupon 22 WO 01/15738 PCT/US00/24058 cells were cultured with a range of NO donor concentrations (1 p.M - 10 mM) in order to identify appropriate dosages for hydrogel studies. NO nucleophile complexes (Lys-NO and DETA-NO) were formed by reacting either L-lysine or DETA with NO gas in water for 24 hours. Soluble Cys 5 NO was synthesized by reacting an equimolar amount of L-cysteine with NaNO 2 at pH 2 and 37oC for 20 minutes. All NO donor solutions were adjusted to pH 7.4 prior to addition to cell cultures. Smooth muscle cell proliferation in the presence of NO-producing and control hydrogels was then investigated using the optimal NO dose 10 determined above. Hydrogels containing acryloyl-PEG-Lys-NO, acryloyl PEG-DETA-NO, and acryloyl-PEG-CYSNO were formed as described above, except that the gel solutions were sterile filtered through 0.2 pm syringe filters (Gelman Sciences, Ann Arbor, MI) prior to adding 2,2 dimethoxy-2-phenyl acetophenone. PEG-diacrylate hydrogels containing no 15 NO donors were used as a control. The hydrogels were photopolymerized in cell culture inserts (8 pm pore size, Becton Dickinson, Franklin Lakes, NJ) and placed in the media over the cultured cells. . All three hydrogel NO donors significantly inhibited SMC growth (p < 0.0001). The number of smooth muscle cells remained near that of the 20 seeding density, which ranged from 10-15% of the final control cell number for all experiments. Inhibition of SMC proliferation by acryloyl-PEG-Lyss-NO hydrogels is shown in Figure 8A, compared to the macromer solution control shown in Figure 8B. Both significantly inhibited SMC proliferation. 25 Inhibition of SMC proliferation by acryloyl-PEG-DETA-NO nucleophile complex hydrogels is shown in Figure 9A, compared to the macromer solution control shown in Figure 9B. Both significantly inhibited SMC proliferation. Inhibition of SMC proliferation by acryloyl-PEG-CYSNO hydrogels 30 is shown in Figure 10 OA, compared to the macromer solution control shown in Figure 10B. Both significantly inhibited SMC proliferation. Inhibition of SMC proliferation by acryloyl-PEG-CYSNO hydrogels, 23 WO 01/15738 PCT/US00/24058 acryloyl-PEG-DETA-NO hydrogels, and acryloyl-PEG-Lys-NO hydrogels is compared to the control hydrogel in Figure 11. All of the NO hydrogels significantly inhibited SMC growth. Example 5: Effects of NO-releasing Macromers on Platelet Adhesion 5 in vitro The effect of NO release on platelet adhesion was investigated to assess the potential of these materials for prevention of thrombosis. Blood was obtained from a healthy volunteer by venipuncture and anticoagulated with 10 U/ml heparin. Platelets and white blood cells were fluorescently 10 labeled with mepacrine at a concentration of 10 pLM. A solution of 2.5 mg/ml collagen I in 3% glacial acetic acid in diH 2 0 was prepared and applied to glass slides for 45 minutes in a humidified environment at room temperature. Acryloyl-PEG-CYSNO and PEG-diacrylate hydrogels were prepared as described above and incubated with the labeled whole blood at 15 37oC for 30 minutes. The hydrogels were removed and the blood was then incubated with the collagen-coated glass slides (two per group) for 20 minutes at 37oC and then rinsed with HBS. Platelet counts per field of view at 40x were counted under a fluorescent microscope (Zeiss Axiovert 135, Thornwood, NY) in four randomly chosen areas per slide. 20 Photos of platelets which had been exposed to control PEG-diacrylate or acryloyl-PEG-CYSNO hydrogels demonstrate that exposure to the NO releasing hydrogels inhibits platelet adhesion to thrombogenic surfaces. Glass slides coated with collagen were used as a thrombogenic surface to which platelets would normally adhere. When the blood was incubated with 25 control PEG-diacrylate hydrogels, 69.25 ± 4.46 (mean ± SD) adherent platelets were observed per field of view. This number was reduced to 7.65 ± 6.16 platelets pre field of view when blood was pre-exposed to the acryloyl-PEG-CYSNO hydrogels (p < 0.0001). 24

Claims (23)

1. A biocompatible, polymerizable, macromer composition comprising at least one NO carrying region or NO modulating compound, wherein NO or NO modulating compound is released from the macromer composition following polymerization, under physiological conditions, wherein the macromers comprise regions selected from the group consisting of water soluble regions, tissue adhesive regions, and polymerizable end group regions.

2. The macromer composition of claim 1 wherein the macromer composition comprises additional macromers which do not release NO following polymerization.

3. The macromer composition of claim 1 wherein the macromer further comprises crosslinkable side groups.

4. The macromer composition of claim 1 wherein the macromer comprises at least one degradable region.

5. The macromer composition of claim 1 wherein the macromer is water soluble.

6. The macromer composition of claim 1 wherein the macromer adheres to tissue.

7. The macromer composition of claim 1 wherein the macromer comprises a water soluble region attached to a degradable region, at least one polymerizable region attached to the water soluble region, and at least one polymerizable region attached to the degradable region.

8. The macromer composition of claim 4 wherein the degradable region is a central core, at least two water soluble regions are attached to the core, and at least one polymerizable region is attached to each water soluble region.

9. The macromer composition of claim 1 wherein the macromer comprises a water soluble region forming a central core, at least two degradable regions attached to the core, and at least two polymerizable regions attached to the degradable regions.

10. The macromer composition of claim 1 further comprising therapeutic, prophylactic or diagnostic agents selected from the group 25 WO 01/15738 PCT/US00/24058 consisting of proteins, carbohydrates, nucleic acids, organic molecules, inorganic biologically active molecules, cells, tissues, and tissue aggregates, and diagnostic agents.

11. The macromer composition of claim 1 wherein the macromer comprises at least one water soluble region, at least one NO carrying region and at least one free radical polymerizable region.

12. The macromer composition of Claim 11 further comprising at least one degradable region.

13. The macromer composition of claim 1 having incorporated therein or releasably bound thereto a compound modulating NO levels under physiological conditions.

14. The macromer composition of claim 1 releasing NO under physiological conditions.

15. A method for modulating NO levels in tissue comprising administering to the tissue any of the macromer compositions of claims 1-14.

16. The method of claim 15 further comprising first applying a polymerization initiator at the site where the macromer composition solution is to be polymerized.

17. The method of claim 16 wherein the initiator binds to the tissue, further comprising removing unbound initiator prior to application of the macromer composition solution.

18. A method for controlled release of therapeutic, prophylactic, or diagnostic agents comprising administering to tissue in need thereof a biocompatible, polymerizable, macromer composition comprising at least one NO carrying region or NO modulating compound, wherein NO or NO modulating compound is released from the macromer composition following polymerization, under physiological conditions, wherein the macromers comprise regions selected from the group consisting of water soluble regions, tissue adhesive regions, and polymerizable end group regions.comprising therapeutic, prophylactic or diagnostic agents selected from the group consisting of proteins, carbohydrates, nucleic acids, organic molecules, inorganic biologically active molecules, cells, tissues, and tissue aggregates, and diagnostic agents. 26 WO 01/15738 PCT/US00/24058

19. A method for making a polymeric composition capable of releasing nitric oxide at physiological pH, the method comprising polymerizing a solution of biocompatible macromers on tissue, wherein the macromers comprise at least one NO carrying or producing region.

20. A method of treating a disorder or condition with NO comprising administering to an individual in need thereof a biocompatible, polymerizable, macromer composition comprising at least one NO carrying region or NO modulating compound, wherein NO or NO modulating compound is released from the macromer composition following polymerization, under physiological conditions, wherein the macromers comprise regions selected from the group consisting of water soluble regions, tissue adhesive regions, and polymerizable end group regions.

21. The method of claim 20 wherein the macromer further comprises degradable regions.

22. The method of claim 20 for treatment of a disorder or condition selected from the group consisting of wound healing, restenosis, thrombosis, asthma, arthritis, and erectile dysfunction.

23. The method of claim 20 wherein the macromer is adhered to tissue to prevent surgical adhesions, adhere tissue , provide support for tissue or coat the tissue. 27